statistiche ricercatore

Continente	#
NA - Nord America	438
AS - Asia	281
EU - Europa	247
SA - Sud America	68
Continente sconosciuto - Info sul continente non disponibili	12
AF - Africa	9
OC - Oceania	1
Totale	1.056

Nazione	#
US - Stati Uniti d'America	419
SG - Singapore	134
CN - Cina	63
SE - Svezia	58
BR - Brasile	57
DE - Germania	52
FR - Francia	46
VN - Vietnam	24
IN - India	20
IT - Italia	20
PL - Polonia	14
GB - Regno Unito	12
ID - Indonesia	10
UA - Ucraina	10
CA - Canada	9
IE - Irlanda	9
HK - Hong Kong	7
CI - Costa d'Avorio	6
FI - Finlandia	6
JP - Giappone	6
RU - Federazione Russa	5
AR - Argentina	4
NL - Olanda	4
TR - Turchia	4
BD - Bangladesh	3
BE - Belgio	3
MX - Messico	3
PK - Pakistan	3
VE - Venezuela	3
AT - Austria	2
ES - Italia	2
EU - Europa	2
IR - Iran	2
NI - Nicaragua	2
PE - Perù	2
AU - Australia	1
CO - Colombia	1
DO - Repubblica Dominicana	1
EC - Ecuador	1
EG - Egitto	1
HN - Honduras	1
HU - Ungheria	1
IL - Israele	1
IQ - Iraq	1
JM - Giamaica	1
KZ - Kazakistan	1
LA - Repubblica Popolare Democratica del Laos	1
LT - Lituania	1
MA - Marocco	1
NO - Norvegia	1
RO - Romania	1
SV - El Salvador	1
TT - Trinidad e Tobago	1
UZ - Uzbekistan	1
XK - ???statistics.table.value.countryCode.XK???	1
ZA - Sudafrica	1
Totale	1.047

Nome	#
A SPRY2 mutation leading to MAPK/ERK pathway inhibition is associated with an autosomal dominant form of IgA nephropathy.	220
Defective activation of the MAPK/ERK pathway, leading to PARP1 and DNMT1 dysregulation, is a common defect in IgA nephropathy and Henoch-Schönlein purpura	152
Rituximab Followed by Belimumab Controls Severe Lupus Nephritis and Bullous Pemphigoid in Systemic Lupus Erythematosus Refractory to Several Combination Therapies	149
Contrast-enhanced ultrasonography in chronic glomerulonephritides: correlation with histological parameters of disease activity	138
Rituximab Followed by Belimumab Controls Severe Lupus Nephritis and Bullous Pemphigoid in Systemic Lupus Erythematosus Refractory to Several Combination Therapies	138
Deterioration in Clinical Status Is Not Enough to Suspend Eculizumab: A Genetic Complement-Mediated Atypical Hemolytic Uremic Syndrome Case Report	134
Combined treatment with renin-angiotensin system blockers and polyunsaturated fatty acids in proteinuric IgA nephropathy: A randomized controlled trial	125
Totale	1.056

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	57	0	0	0	0	5	2	0	13	4	4	13	16
2022/2023	181	26	22	12	34	7	26	15	13	19	0	5	2
2023/2024	62	3	14	1	7	0	8	6	1	0	4	9	9
2024/2025	138	1	1	11	6	11	7	2	8	16	19	33	23
2025/2026	372	64	4	27	52	82	24	56	15	23	14	3	8
2026/2027	96	9	10	25	48	4	0	0	0	0	0	0	0
Totale													1.056

IRIS UniCatt